arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Chemomab Therapeutics Ltd.

CMMB

$1.30 ▲ +0.08 (+6.56%) at close

10 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Chemomab Therapeutics Ltd. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $663.3M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -908.1% ↘

FCF / Share $-0.02 ↗

Trailing P/E 72.2x

Price / Book 53.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-8.99M

↑ +35.5% —

FCF / Share Free cash flow per share

$-0.02

↑ +49.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
EPS Growth YoY (%)	-53.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-62.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-14.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	101.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	35.5% Excellent ↑ Excellent Improving Year-over-year change in net income	42.4% Excellent ↑ Excellent Improving Year-over-year change in net income	12.4% Fair ↑ Fair Improving Year-over-year change in net income	-121.6% Weak ↓ Weak Declining Year-over-year change in net income	-7.5% Weak ↑ Weak Improving Year-over-year change in net income	57.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-96.6% Weak ↓ Weak Declining Year-over-year change in net income	-40.7% Weak Weak Year-over-year change in net income	-106.8% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	49.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	57.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-11.9% Weak Weak Year-over-year change in free cash flow	-47.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—
EPS CAGR 3Y (%)	-47.0% Weak Weak Compound annual EPS growth over 3 years	-13.4% Weak Weak Compound annual EPS growth over 3 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.9% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	1.24x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Return on Invested Capital (%)	-908.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-760.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—	—	—
Return on Capital (%) (%)	-810.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-607.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—	—	—
Return on Common Equity (%) (%)	-72.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-586%)	-103.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-787%)	-142.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1050%)	-76.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-609%)	-20.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	—	-181.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1313%)	-140.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1038%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Net Debt (USD)	$-7.56M	$-6.07M	$-9.29M	$-13.52M	$-15.19M	$-5.39M	$-17.57M	$-7.52M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Basic EPS, GAAP (USD)	$0.02	$0.04	$0.10	$0.12	$0.06	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.02	$-0.04	$-0.10	$-0.09	$-0.06	—	—	—	—	—
Book Value per Share (USD)	$0.02	$0.04	$0.07	$0.16	$0.30	$0.60	$2.51	$3.93	—	—
Tangible Book Value per Share (USD)	$0.02	$0.04	$0.07	$0.16	$0.30	$0.60	$2.51	$3.93	—	—
Basic Weighted Avg Shares (shares)	510.23M	359.05M	235.00M	227.59M	207.47M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Working Capital (USD)	$11.95M	$12.82M	$16.06M	$34.99M	$60.04M	$3.53M	$14.09M	$8.17M	—	—
Total Equity (USD)	$12.33M	$13.54M	$17.00M	$36.22M	$61.47M	$3.58M	$14.91M	$9.80M	—	—

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 20-F ↗	FY 2016 Dec 31, 2016 20-F ↗
Depreciation Expense (USD)	$70.00K	$53.00K	$67.00K	$58.00K	$34.00K	$80.00K	$281.00K	$66.00K	—	—
Net Income, GAAP (USD)	$-8.99M	$-13.95M	$-24.22M	$-27.65M	$-12.48M	$-11.61M	$-27.12M	$-13.80M	$-9.81M	$-4.74M
Operating Cash Flow (USD)	$-11.13M	$-15.39M	$-23.61M	$-20.37M	$-12.37M	$-12.71M	$-16.46M	$-14.22M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 22 quarters

Chemomab Therapeutics Ltd.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CMMB with peers